Explore the Agenda
8:00 am Check In & Registration
8:45 am Chair’s Opening Remarks
Enhancing Conjugation Chemistry for Unlocking Synergistic Potential In Dual Payload ADCs
9:30 am Next-Generation Multi-Payload ADCs: How Site-Selective Conjugations Enable New Modalities
- Potential of dual-payload ADCs and challenges presented by traditional conjugation approaches
- Review of approaches to manufacturing dual-payload ADCs, with focus on the CysTyr platform for site-specific conjugation
- Efficacy of Multi-Payload Conjugates produced using CysTyr conjugation
10:00 am Development of a Site Specific & Versatile Conjugation Approach Based On Bacterial Transglutaminase & the Diels-Alder Cycloaddition Reaction for ADCs
- The versatility of maleimides for the conjugation to antibodies – a different application that specifically conjugates via cycloaddition reaction vs conjugation to interchain disulfides or engineered cysteines
- Design and synthesis of the diene-containing linkers for site specific transglutaminase conjugation for two different payloads
- Evaluation of the in vitro and in vivo activity and stability of the ADCs generated via this transglutaminase – Diels-Alder approach
10:30 am Morning Break & Speed Networking
11:30 am Designing Branched Linkers for Dual Payload ADCs to Balance Synergy & Selectivity
- Investigating chemical engineering strategies for designing branch linkers for achieving distinct tumor-specific cleavage mechanisms
- Addressing challenges in maintaining payload stability and ensuring effective payload release while preserving the overall functionality of the ADC
- Exploring the use of modified conjugation methods to achieve controlled ratios of each payload, ensuring synergistic effects without compromising safety or efficacy
12:00 pm Targeting Solid Tumors & Hematological Malignancies with ADCs Utilizing Auristatin, Topo1i & Dual Payloads
- Hydrophilic linker with optimized cleavable moiety enables efficient auristatin, exatecan / topoisomerase 1 and novel modality linker-payloads for ADC generation
- DAR4 and DAR8 MMAU auristatin ADCs showed outstanding therapeutic window against solid tumors and hematological malignancies
- Utilizing optimized linker and conjugation technologies for dual-payload ADCs
12:30 pm Lunch
Advancing Linker Design Strategies for Achieving the Optimal Stability Profile
1:30 pm Exploring the Linkers & Architectures of Bicycle® Constructs
- Bicyclic peptides (Bicycles®) as a new targeting modality
- Differences between Bicycles-Conjugates and Antibody-Conjugates
- Linkers, conjugations and architectures of Bicycle constructs
2:00 pm The Story of the B7-H7 Targeting ADC: Exploring a Proprietary Linker for Maximal Compatibility with Targeting Biology
- Attributes of B7-H7 as a tumor target
- ADC linker approach for addressing the vast B7-H7 positive patient population
- NPX125 linker design and attributes
2:30 pm Afternoon Break & Scientific Poster Session
This is an informal session to help you connect with your peers in a relaxed atmosphere and forge new, beneficial relationships. With an audience of linker & conjugation experts looking to stay on top of this evolving space, this is your chance to present, review and discuss posters featuring cutting-edge work.
3:30 pm Exploring Click-Cleavable ADCs & Their Application Scope
- Understanding limitations of current ADC linkers
- Exploring the principle and design of click-cleavable ADC linkers
- Targeting scope expansion and potential for improved efficacy and safety offered by click-cleavable ADCs
4:00 pm Roundtable Discussion: Stable Versus Unstable Linkers for Optimizing Therapeutic Outcomes of ADCs
- Exploring the pros and cons of linker stability in ADC efficacy and toxicity
- Evaluating how stable linkers may prevent deconjugation, while unstable linkers can offer quicker payload release and enhance the bystander effect
- Discussing the balance between stability and controlled cleavage for optimized therapeutic outcomes